Featured NCPD Activity

How Would You Treat This Patient?


Add a heading 150 100 px 200 150 px 300 150 px 500 150 px

Faculty Spotlight

“Not much is spoken about this, and we have a different set of options than we do for other kinds of lung cancers. I think it's vital that we talk about squamous cell lung cancers in particular, in order to highlight the differences from other kinds of lung cancers and strategies for their care.” - Mark Kris, MD.

Mark G. Kris, MD, is the William and Joy Ruane Chair in Thoracic Oncology and Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, where he specializes in the treatment of patients with lung cancer, thymoma, and mediastinal tumors. His research focuses on the identification of genetic targets to develop novel therapeutic strategies for patients with lung cancer. Dr. Kris has served as principal investigator or co-investigator of numerous clinical trials.

“With all the various cancer treatments available to patients currently, providers need to know the differences between chemotherapy, monoclonal antibodies, and immunotherapy in order to understand the adverse events associated with each one.” - Victoria Sherry, DNP, CRNP, AOCNP®

Victoria Sherry, DNP, CRNP, AOCNP®, is a nurse practitioner at the University of Pennsylvania Abramson Cancer Center, where she specializes in the treatment of patients with lung cancer and other thoracic malignancies. She has particular expertise in supportive care and adverse event management for patients with lung cancer receiving novel therapies. Dr. Sherry has authored or coauthored several peer-reviewed publications focused on improving lung cancer care.


Earn CME | NCPD | CPE on the go by listening to this accredited activity as a podcast. Click HERE to start listening now!

Additional Resources

For additional information and unique perspectives on multiple myeloma treatment and patient care, check out the expert interviews listed below.

Add a heading 150 100 px 200 150 px 300 150 px 500 150 px

Copyright © 2022 i3 Health. All rights reserved.